nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—asthma—chronic obstructive pulmonary disease	0.629	1	CtDrD
Loratadine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0252	0.0928	CbGbCtD
Loratadine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0252	0.0928	CbGbCtD
Loratadine—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0227	0.0838	CbGbCtD
Loratadine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0209	0.0771	CbGbCtD
Loratadine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0209	0.0771	CbGbCtD
Loratadine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0191	0.0705	CbGbCtD
Loratadine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0191	0.0705	CbGbCtD
Loratadine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0171	0.0629	CbGbCtD
Loratadine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0161	0.0592	CbGbCtD
Loratadine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0159	0.0585	CbGbCtD
Loratadine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0108	0.04	CbGbCtD
Loratadine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0106	0.039	CbGbCtD
Loratadine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0103	0.0381	CbGbCtD
Loratadine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00922	0.034	CbGbCtD
Loratadine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00903	0.0333	CbGbCtD
Loratadine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00853	0.0314	CbGbCtD
Loratadine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00541	0.0199	CbGbCtD
Loratadine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00511	0.0188	CbGbCtD
Loratadine—Ketotifen—PDE4A—chronic obstructive pulmonary disease	0.0016	0.678	CrCbGaD
Loratadine—Desloratadine—CYP1A2—chronic obstructive pulmonary disease	0.000756	0.322	CrCbGaD
Loratadine—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00338	CcSEcCtD
Loratadine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000257	0.00337	CcSEcCtD
Loratadine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000256	0.00335	CcSEcCtD
Loratadine—Viral infection—Prednisone—chronic obstructive pulmonary disease	0.000255	0.00333	CcSEcCtD
Loratadine—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000254	0.00333	CcSEcCtD
Loratadine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000253	0.00332	CcSEcCtD
Loratadine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000252	0.0033	CcSEcCtD
Loratadine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000251	0.00328	CcSEcCtD
Loratadine—Tension—Formoterol—chronic obstructive pulmonary disease	0.000251	0.00328	CcSEcCtD
Loratadine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.00328	CcSEcCtD
Loratadine—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00328	CcSEcCtD
Loratadine—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00327	CcSEcCtD
Loratadine—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00327	CcSEcCtD
Loratadine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00325	CcSEcCtD
Loratadine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00325	CcSEcCtD
Loratadine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000248	0.00324	CcSEcCtD
Loratadine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00324	CcSEcCtD
Loratadine—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.0032	CcSEcCtD
Loratadine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000244	0.00319	CcSEcCtD
Loratadine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000241	0.00316	CcSEcCtD
Loratadine—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.00024	0.00315	CcSEcCtD
Loratadine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.0031	CcSEcCtD
Loratadine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000237	0.0031	CcSEcCtD
Loratadine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.0031	CcSEcCtD
Loratadine—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00309	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000235	0.00308	CcSEcCtD
Loratadine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00307	CcSEcCtD
Loratadine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00307	CcSEcCtD
Loratadine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00307	CcSEcCtD
Loratadine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000234	0.00306	CcSEcCtD
Loratadine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00305	CcSEcCtD
Loratadine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00305	CcSEcCtD
Loratadine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.00304	CcSEcCtD
Loratadine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00301	CcSEcCtD
Loratadine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00301	CcSEcCtD
Loratadine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00301	CcSEcCtD
Loratadine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00299	CcSEcCtD
Loratadine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.00298	CcSEcCtD
Loratadine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00295	CcSEcCtD
Loratadine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00295	CcSEcCtD
Loratadine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00293	CcSEcCtD
Loratadine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00293	CcSEcCtD
Loratadine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000223	0.00292	CcSEcCtD
Loratadine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00292	CcSEcCtD
Loratadine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00292	CcSEcCtD
Loratadine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.0029	CcSEcCtD
Loratadine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000221	0.00289	CcSEcCtD
Loratadine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00289	CcSEcCtD
Loratadine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000221	0.00289	CcSEcCtD
Loratadine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.00289	CcSEcCtD
Loratadine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00288	CcSEcCtD
Loratadine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00286	CcSEcCtD
Loratadine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00285	CcSEcCtD
Loratadine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00285	CcSEcCtD
Loratadine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00285	CcSEcCtD
Loratadine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00285	CcSEcCtD
Loratadine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00285	CcSEcCtD
Loratadine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00283	CcSEcCtD
Loratadine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00283	CcSEcCtD
Loratadine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00283	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00283	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00283	CcSEcCtD
Loratadine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00281	CcSEcCtD
Loratadine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00281	CcSEcCtD
Loratadine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000213	0.00279	CcSEcCtD
Loratadine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00279	CcSEcCtD
Loratadine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00278	CcSEcCtD
Loratadine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00278	CcSEcCtD
Loratadine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.00277	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000212	0.00277	CcSEcCtD
Loratadine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00276	CcSEcCtD
Loratadine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00275	CcSEcCtD
Loratadine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.00273	CcSEcCtD
Loratadine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000209	0.00273	CcSEcCtD
Loratadine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00273	CcSEcCtD
Loratadine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00269	CcSEcCtD
Loratadine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00269	CcSEcCtD
Loratadine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00268	CcSEcCtD
Loratadine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00268	CcSEcCtD
Loratadine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00267	CcSEcCtD
Loratadine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00267	CcSEcCtD
Loratadine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00266	CcSEcCtD
Loratadine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00266	CcSEcCtD
Loratadine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00266	CcSEcCtD
Loratadine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00265	CcSEcCtD
Loratadine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00265	CcSEcCtD
Loratadine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00263	CcSEcCtD
Loratadine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000201	0.00262	CcSEcCtD
Loratadine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00262	CcSEcCtD
Loratadine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000198	0.0026	CcSEcCtD
Loratadine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00258	CcSEcCtD
Loratadine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000195	0.00255	CcSEcCtD
Loratadine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.00255	CcSEcCtD
Loratadine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00253	CcSEcCtD
Loratadine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00253	CcSEcCtD
Loratadine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00251	CcSEcCtD
Loratadine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.0025	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00249	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00249	CcSEcCtD
Loratadine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000189	0.00247	CcSEcCtD
Loratadine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.00247	CcSEcCtD
Loratadine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000188	0.00245	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00243	CcSEcCtD
Loratadine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00243	CcSEcCtD
Loratadine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00243	CcSEcCtD
Loratadine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000185	0.00242	CcSEcCtD
Loratadine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.00241	CcSEcCtD
Loratadine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000184	0.0024	CcSEcCtD
Loratadine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.0024	CcSEcCtD
Loratadine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000183	0.0024	CcSEcCtD
Loratadine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00238	CcSEcCtD
Loratadine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000181	0.00237	CcSEcCtD
Loratadine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00236	CcSEcCtD
Loratadine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00236	CcSEcCtD
Loratadine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00235	CcSEcCtD
Loratadine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00235	CcSEcCtD
Loratadine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00235	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00235	CcSEcCtD
Loratadine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00233	CcSEcCtD
Loratadine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00231	CcSEcCtD
Loratadine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00231	CcSEcCtD
Loratadine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000176	0.0023	CcSEcCtD
Loratadine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00229	CcSEcCtD
Loratadine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00229	CcSEcCtD
Loratadine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000174	0.00228	CcSEcCtD
Loratadine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00227	CcSEcCtD
Loratadine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000173	0.00226	CcSEcCtD
Loratadine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000173	0.00226	CcSEcCtD
Loratadine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00225	CcSEcCtD
Loratadine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00225	CcSEcCtD
Loratadine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000172	0.00225	CcSEcCtD
Loratadine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000171	0.00224	CcSEcCtD
Loratadine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00223	CcSEcCtD
Loratadine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00223	CcSEcCtD
Loratadine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00223	CcSEcCtD
Loratadine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00222	CcSEcCtD
Loratadine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00222	CcSEcCtD
Loratadine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.0022	CcSEcCtD
Loratadine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.0022	CcSEcCtD
Loratadine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00219	CcSEcCtD
Loratadine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00216	CcSEcCtD
Loratadine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00216	CcSEcCtD
Loratadine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00216	CcSEcCtD
Loratadine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00216	CcSEcCtD
Loratadine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000164	0.00215	CcSEcCtD
Loratadine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00213	CcSEcCtD
Loratadine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00213	CcSEcCtD
Loratadine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00213	CcSEcCtD
Loratadine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00212	CcSEcCtD
Loratadine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000162	0.00212	CcSEcCtD
Loratadine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000161	0.00211	CcSEcCtD
Loratadine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000161	0.00211	CcSEcCtD
Loratadine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00211	CcSEcCtD
Loratadine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00204	CcSEcCtD
Loratadine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00204	CcSEcCtD
Loratadine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000154	0.00201	CcSEcCtD
Loratadine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00196	CcSEcCtD
Loratadine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00196	CcSEcCtD
Loratadine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000147	0.00192	CcSEcCtD
Loratadine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.00187	CcSEcCtD
Loratadine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000143	0.00187	CcSEcCtD
Loratadine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00186	CcSEcCtD
Loratadine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00185	CcSEcCtD
Loratadine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00014	0.00183	CcSEcCtD
Loratadine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.0018	CcSEcCtD
Loratadine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000138	0.0018	CcSEcCtD
Loratadine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000135	0.00177	CcSEcCtD
Loratadine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.00176	CcSEcCtD
Loratadine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000133	0.00173	CcSEcCtD
Loratadine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000133	0.00173	CcSEcCtD
Loratadine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000132	0.00172	CcSEcCtD
Loratadine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000132	0.00172	CcSEcCtD
Loratadine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00172	CcSEcCtD
Loratadine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00172	CcSEcCtD
Loratadine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00171	CcSEcCtD
Loratadine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00171	CcSEcCtD
Loratadine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.0017	CcSEcCtD
Loratadine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00013	0.0017	CcSEcCtD
Loratadine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000129	0.00169	CcSEcCtD
Loratadine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000129	0.00168	CcSEcCtD
Loratadine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.00168	CcSEcCtD
Loratadine—Depression—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00168	CcSEcCtD
Loratadine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000128	0.00167	CcSEcCtD
Loratadine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.00165	CcSEcCtD
Loratadine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.00164	CcSEcCtD
Loratadine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.00163	CcSEcCtD
Loratadine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00162	CcSEcCtD
Loratadine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00162	CcSEcCtD
Loratadine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00162	CcSEcCtD
Loratadine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00162	CcSEcCtD
Loratadine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00162	CcSEcCtD
Loratadine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.00161	CcSEcCtD
Loratadine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000122	0.00159	CcSEcCtD
Loratadine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000121	0.00159	CcSEcCtD
Loratadine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.00156	CcSEcCtD
Loratadine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00153	CcSEcCtD
Loratadine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.00152	CcSEcCtD
Loratadine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.00148	CcSEcCtD
Loratadine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.00145	CcSEcCtD
Loratadine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.00144	CcSEcCtD
Loratadine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00137	CcSEcCtD
Loratadine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00135	CcSEcCtD
Loratadine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.00134	CcSEcCtD
Loratadine—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000102	0.00134	CcSEcCtD
Loratadine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.00133	CcSEcCtD
Loratadine—Pain—Prednisolone—chronic obstructive pulmonary disease	9.66e-05	0.00126	CcSEcCtD
Loratadine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	9.33e-05	0.00122	CcSEcCtD
Loratadine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.31e-05	0.00122	CcSEcCtD
Loratadine—Agitation—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.00121	CcSEcCtD
Loratadine—Angioedema—Prednisone—chronic obstructive pulmonary disease	9.19e-05	0.0012	CcSEcCtD
Loratadine—Malaise—Prednisone—chronic obstructive pulmonary disease	9.07e-05	0.00119	CcSEcCtD
Loratadine—Syncope—Prednisone—chronic obstructive pulmonary disease	9.02e-05	0.00118	CcSEcCtD
Loratadine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.84e-05	0.00116	CcSEcCtD
Loratadine—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.68e-05	0.00114	CcSEcCtD
Loratadine—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.56e-05	0.00112	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.5e-05	0.00111	CcSEcCtD
Loratadine—Discomfort—Prednisone—chronic obstructive pulmonary disease	8.46e-05	0.00111	CcSEcCtD
Loratadine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.00107	CcSEcCtD
Loratadine—Shock—Prednisone—chronic obstructive pulmonary disease	8.08e-05	0.00106	CcSEcCtD
Loratadine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.05e-05	0.00105	CcSEcCtD
Loratadine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.00105	CcSEcCtD
Loratadine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.97e-05	0.00104	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.48e-05	0.000978	CcSEcCtD
Loratadine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.47e-05	0.000977	CcSEcCtD
Loratadine—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.42e-05	0.000971	CcSEcCtD
Loratadine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.37e-05	0.000964	CcSEcCtD
Loratadine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000945	CcSEcCtD
Loratadine—Rash—Prednisolone—chronic obstructive pulmonary disease	7.12e-05	0.000932	CcSEcCtD
Loratadine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.12e-05	0.000931	CcSEcCtD
Loratadine—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.08e-05	0.000926	CcSEcCtD
Loratadine—Headache—Prednisolone—chronic obstructive pulmonary disease	7.08e-05	0.000926	CcSEcCtD
Loratadine—Constipation—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000918	CcSEcCtD
Loratadine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.76e-05	0.000885	CcSEcCtD
Loratadine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000878	CcSEcCtD
Loratadine—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.71e-05	0.000878	CcSEcCtD
Loratadine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.49e-05	0.000849	CcSEcCtD
Loratadine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.49e-05	0.000849	CcSEcCtD
Loratadine—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	6.2e-05	0.003	CbGpPWpGaD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.03e-05	0.00292	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	6.02e-05	0.00291	CbGpPWpGaD
Loratadine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	6.01e-05	0.00291	CbGpPWpGaD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	5.98e-05	0.00289	CbGpPWpGaD
Loratadine—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.00077	CcSEcCtD
Loratadine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.88e-05	0.00284	CbGpPWpGaD
Loratadine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.8e-05	0.0028	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	5.67e-05	0.00274	CbGpPWpGaD
Loratadine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.62e-05	0.000735	CcSEcCtD
Loratadine—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.43e-05	0.00071	CcSEcCtD
Loratadine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.4e-05	0.00261	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	5.39e-05	0.00261	CbGpPWpGaD
Loratadine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.36e-05	0.00259	CbGpPWpGaD
Loratadine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.34e-05	0.00258	CbGpPWpGaD
Loratadine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.33e-05	0.00258	CbGpPWpGaD
Loratadine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.29e-05	0.00256	CbGpPWpGaD
Loratadine—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.22e-05	0.000683	CcSEcCtD
Loratadine—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	5.2e-05	0.00252	CbGpPWpGaD
Loratadine—Rash—Prednisone—chronic obstructive pulmonary disease	5.18e-05	0.000677	CcSEcCtD
Loratadine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.17e-05	0.000676	CcSEcCtD
Loratadine—Headache—Prednisone—chronic obstructive pulmonary disease	5.14e-05	0.000673	CcSEcCtD
Loratadine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	4.97e-05	0.0024	CbGpPWpGaD
Loratadine—Nausea—Prednisone—chronic obstructive pulmonary disease	4.88e-05	0.000638	CcSEcCtD
Loratadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	4.86e-05	0.00235	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	4.85e-05	0.00235	CbGpPWpGaD
Loratadine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	4.8e-05	0.00232	CbGpPWpGaD
Loratadine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.76e-05	0.0023	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.69e-05	0.00227	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.64e-05	0.00224	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	4.64e-05	0.00224	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	4.62e-05	0.00223	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	4.61e-05	0.00223	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	4.52e-05	0.00218	CbGpPWpGaD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.38e-05	0.00212	CbGpPWpGaD
Loratadine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	4.37e-05	0.00211	CbGpPWpGaD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.34e-05	0.0021	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.33e-05	0.00209	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	4.3e-05	0.00208	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.19e-05	0.00203	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.14e-05	0.002	CbGpPWpGaD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	3.94e-05	0.00191	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	3.91e-05	0.00189	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.9e-05	0.00189	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.85e-05	0.00186	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.85e-05	0.00186	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.82e-05	0.00185	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.81e-05	0.00184	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.78e-05	0.00183	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.67e-05	0.00177	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	3.62e-05	0.00175	CbGpPWpGaD
Loratadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	3.53e-05	0.00171	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	3.52e-05	0.0017	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	3.5e-05	0.00169	CbGpPWpGaD
Loratadine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	3.49e-05	0.00169	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.48e-05	0.00168	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.43e-05	0.00166	CbGpPWpGaD
Loratadine—HRH1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	3.42e-05	0.00165	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	3.38e-05	0.00163	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.3e-05	0.0016	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.25e-05	0.00157	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.21e-05	0.00155	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.2e-05	0.00155	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.18e-05	0.00154	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.16e-05	0.00153	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.14e-05	0.00152	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.13e-05	0.00151	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	3.06e-05	0.00148	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.99e-05	0.00145	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.95e-05	0.00143	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.95e-05	0.00142	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.9e-05	0.0014	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	2.9e-05	0.0014	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	2.88e-05	0.00139	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.86e-05	0.00138	CbGpPWpGaD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	2.86e-05	0.00138	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.83e-05	0.00137	CbGpPWpGaD
Loratadine—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.8e-05	0.00135	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.69e-05	0.0013	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.67e-05	0.00129	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.67e-05	0.00129	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	2.65e-05	0.00128	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.65e-05	0.00128	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	2.64e-05	0.00128	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.63e-05	0.00127	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.63e-05	0.00127	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.61e-05	0.00126	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	2.59e-05	0.00125	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	2.55e-05	0.00123	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.54e-05	0.00123	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.53e-05	0.00122	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.52e-05	0.00122	CbGpPWpGaD
Loratadine—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.5e-05	0.00121	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.49e-05	0.0012	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	2.49e-05	0.0012	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.47e-05	0.00119	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.45e-05	0.00119	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.43e-05	0.00118	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.42e-05	0.00117	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.4e-05	0.00116	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.33e-05	0.00113	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.31e-05	0.00112	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.3e-05	0.00111	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	2.28e-05	0.0011	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.28e-05	0.0011	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2.27e-05	0.0011	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	2.24e-05	0.00108	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	2.21e-05	0.00107	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	2.16e-05	0.00104	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.09e-05	0.00101	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.07e-05	0.000998	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.04e-05	0.000984	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.99e-05	0.000961	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	1.99e-05	0.000961	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	1.98e-05	0.000957	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.97e-05	0.000953	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	1.87e-05	0.000905	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	1.86e-05	0.000897	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	1.85e-05	0.000893	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.81e-05	0.000873	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.75e-05	0.000844	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.75e-05	0.000844	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.72e-05	0.000834	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.72e-05	0.000833	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.63e-05	0.000786	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.6e-05	0.000776	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.58e-05	0.000765	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.52e-05	0.000736	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.51e-05	0.00073	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.5e-05	0.000725	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.5e-05	0.000724	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	1.47e-05	0.00071	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.45e-05	0.000702	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.4e-05	0.000677	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.38e-05	0.000668	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.37e-05	0.00066	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.35e-05	0.000652	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.34e-05	0.000646	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.32e-05	0.00064	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.32e-05	0.00064	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.32e-05	0.000636	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.31e-05	0.000634	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.28e-05	0.000619	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.25e-05	0.000603	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.24e-05	0.0006	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.23e-05	0.000594	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.22e-05	0.000592	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.22e-05	0.00059	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.22e-05	0.000589	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.21e-05	0.000583	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.2e-05	0.000578	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.19e-05	0.000575	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.13e-05	0.000547	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.12e-05	0.000542	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.11e-05	0.000539	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.11e-05	0.000538	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.09e-05	0.000526	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.07e-05	0.000515	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.07e-05	0.000515	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.06e-05	0.000514	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.06e-05	0.000513	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.02e-05	0.000494	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.01e-05	0.000489	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	9.76e-06	0.000472	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	9.75e-06	0.000471	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.72e-06	0.00047	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	9.57e-06	0.000463	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	9.12e-06	0.000441	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.86e-06	0.000428	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	8.85e-06	0.000428	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.11e-06	0.000392	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	8.04e-06	0.000389	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.03e-06	0.000388	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	7.94e-06	0.000384	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	7.89e-06	0.000381	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.8e-06	0.000377	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.4e-06	0.000358	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.33e-06	0.000355	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.25e-06	0.00035	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	7.24e-06	0.00035	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.17e-06	0.000346	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.08e-06	0.000342	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.99e-06	0.000338	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	6.91e-06	0.000334	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.69e-06	0.000323	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.67e-06	0.000323	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.6e-06	0.000319	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.59e-06	0.000319	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.53e-06	0.000316	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	6.51e-06	0.000315	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	6.46e-06	0.000312	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	6.46e-06	0.000312	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	6.31e-06	0.000305	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.13e-06	0.000296	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.02e-06	0.000291	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.02e-06	0.000291	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.98e-06	0.000289	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.96e-06	0.000288	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.94e-06	0.000287	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	5.89e-06	0.000285	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.81e-06	0.000281	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.56e-06	0.000269	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.49e-06	0.000265	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.48e-06	0.000265	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.47e-06	0.000264	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.43e-06	0.000263	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.43e-06	0.000263	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.23e-06	0.000253	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.11e-06	0.000247	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.97e-06	0.00024	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.9e-06	0.000237	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.86e-06	0.000235	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.85e-06	0.000234	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.85e-06	0.000234	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.78e-06	0.000231	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.57e-06	0.000221	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.56e-06	0.000221	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.53e-06	0.000219	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.51e-06	0.000218	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.47e-06	0.000216	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.45e-06	0.000215	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.33e-06	0.000209	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.31e-06	0.000208	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.26e-06	0.000206	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.22e-06	0.000204	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.2e-06	0.000203	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.16e-06	0.000201	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4e-06	0.000193	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.98e-06	0.000192	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.95e-06	0.000191	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.89e-06	0.000188	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.81e-06	0.000184	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.64e-06	0.000176	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.58e-06	0.000173	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.3e-06	0.000159	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.23e-06	0.000156	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.15e-06	0.000152	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.07e-06	0.000149	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.99e-06	0.000144	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.95e-06	0.000142	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	2.94e-06	0.000142	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.92e-06	0.000141	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.87e-06	0.000139	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.81e-06	0.000136	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.75e-06	0.000133	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.74e-06	0.000133	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.71e-06	0.000131	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.68e-06	0.00013	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.62e-06	0.000127	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.6e-06	0.000126	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.59e-06	0.000125	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.57e-06	0.000124	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.41e-06	0.000116	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.36e-06	0.000114	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.98e-06	9.58e-05	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.81e-06	8.77e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.77e-06	8.55e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.69e-06	8.18e-05	CbGpPWpGaD
